Spectral AI ( (MDAI) ) has issued an announcement.
On March 26, 2025, Spectral AI’s Board of Directors approved an amendment to CFO Vincent Capone’s employment agreement, enhancing his compensation and stock options. The company announced its 2024 financial results, highlighting a significant increase in R&D revenue due to its BARDA PBS contract. Spectral AI is advancing its DeepView System for regulatory approval in the US, supported by successful burn validation study results. The company is on track to submit regulatory filings for its burn indication and anticipates FDA clearance in early 2026, with commercial product revenue expected in the second half of 2025.
More about Spectral AI
Spectral AI, Inc. is an artificial intelligence company specializing in medical diagnostics aimed at improving treatment decisions in wound care. The company focuses on the development and commercialization of its AI-Driven DeepView System, which is designed to enhance wound healing assessments and is expected to generate commercial revenue across multiple platforms within the next three years.
YTD Price Performance: -56.04%
Average Trading Volume: 688,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: $29.12M
See more insights into MDAI stock on TipRanks’ Stock Analysis page.